Selected highlights from the European Academy of Neurology annual meeting, Vienna, Austria, June 25-28, 2022.
June 30 Edition
June 29 Edition
Relapses uncommon after COVID vaccination
The aging MS patient
Ocrelizumab EID
Natalizumab EID
Clinical tip of the day
Read More
The U.S. Food and Drug Administration will meet later this month to consider approval of two bivalent COVID-19 booster vaccines that are reportedly effective against the Omicron variant (B.1.1.529). Both boosters were developed by Moderna and are variations of the company’s original mRNA-1273 vaccine. Read More
Click here to watch Dr. Courtney Casserly discuss the case and the responses to the survey.
Alison, 31, is a lawyer, married with no children. She was diagnosed with RRMS in 2014. Her initial presentation was vertigo, diplopia and mild ataxia. EDSS score was 2.0. She was started on glatiramer acetate but was switched to fingolimod in 2016 after experiencing two relapses. Read More
Includes a comparison of anti-CD20 therapies (rituximab, ocrelizumab, ofatumumab), depth and duration of B cell suppression, time to B cell reconstitution, and current data on reduced-dose regimens, extended-interval dosing and personalized dosing.
14 slides